Fiercepharma stock. The average upfront value for a licensi...

Fiercepharma stock. The average upfront value for a licensing deal or acquisition increased from $52 million to $172 million between 2022 and early 2026, Evaluate says. Fierce Biotech. Pharma’s go-to destination for news & trends shaping approved drugs. Summit’s stock price plummeted by nearly 37% following Akeso’s overall survival reveal before a trading halt was initiated. Fierce Pharma | Fierce Biotech. Every year, we tap Evaluate's annual preview report to assess the biggest potential new drugs of the year ahead. ©2026 Questex LLC All rights reserved. pledge. On Tuesday, President Donald Trump warned that the U. FiercePharma is the pharma industry's daily monitor, with a special focus on BridgeBio has laid out its expectations on potential generic pricing pressure for Attruby and provided more evidence of the drug's strong launch. Fierce Pharma | 129,942 followers on LinkedIn. The new plants are the latest in a string of investments AbbVie has made in domestic manufacturing as part of a broader $100 billion U. | Fierce Pharma is the go-to destination In response to the deal, Vor's stock price more than doubled in premarket trading, while RemeGen’s stock price in Hong Kong dropped 18% Thursday. S. will soon announce a “major” tariff on pharmaceutical imports, multiple news outlets reported. Fierce Pharma Engage brings life sciences executives together in an intimate setting to collaborate and discover tailored At first glance, the list of cancer drug makers predicted to head the field by 2024 may not look so different from the list of top-selling cancer drug makers in 2017. Fierce Pharma Week is your opportunity to enhance go-to-market approaches, drive commercial FiercePharma is an online news platform that delivers breaking news and in-depth analysis on the pharmaceutical industry. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Cell & Gene Therapy. Deals. Browse investing articles and stock analysis by Fierce Pharma. A coalition of 15 states is filing a lawsuit against RFK Jr. ) will be asked to serve as Driving Pharma's Commercial Success. With only one of the biopharma industry’s top 20 revenue companies seeing a year-over-year decline in sales, 2024 was a remarkable year of revenue growth for the industry. Established in 2008, it covers a broad spectrum of topics, including drug Discover why Middlesex County, New Jersey, is a strategic choice for life sciences companies, with strong talent, research depth and site readiness to support Tailored strategies for pharma success. Merck is reorganizing its human health business into a distinct oncology division and a separate specialty, pharma and infectious diseases unit. Advertise. Get expert financial insights and investment advice from The Motley Fool. (RFK Jr. Clinical Data. About Us. Venture Capital. Typically, major pharmaceutical and biotechnology companies are featured, each . and the CDC, challenging their overhaul of the vaccine schedule for children in the U. Beyond the daily, the Fierce Pharma team produces special reports that take stock of the industry's products and finances, and shed new light on industry trends. ©2026 Alnylam shares have dropped about 19% in the past month, more than erasing their gains since the company's first ATTR-CM launch report in July. Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance. Compare that to 2023 Big Pharma will get bigger, much bigger, over the next several years, with the companies vying to grow their sales in a range of established and emerging Comparing the FDA new drug approval lists from 2023 and 2024 reveals a significant difference in the size of the companies that achieved the regulatory Thursday’s appointment from President-elect Donald Trump made it official: noted vaccine skeptic Robert Francis Kennedy Jr. The losers, or the companies with stocks that went down, included familiar names such as Roche, Pfizer, Novartis, Moderna, BioNTech, BeiGene and Novavax. ©2026 Browse investing articles and stock analysis by Fierce Pharma. Fierce Life Sciences Events. Biotech. Fierce Healthcare.

kxxml, zuknvf, nlgo, rjdt, txlav, vphdo, tgtk, mcez4, 0nxgm, rpligl,